具体实施方式
以下通过多西紫杉醇(Docetaxel)与胞壁酰二肽(MDP)简化物的共缀物(MDC)合成和生物学的优选实施例具体说明本发明的各个方面和特征。本领域的技术人员应该理解,这些实施例只是用于说明目的,而不限制本发明的范围。本发明的保护范围只受权利要求书的限制。在不背离权利要求书范围的条件下,本领域的技术人员可以对本发明的各个方面进行各种修改和改进,这些修改和改进也属于本发明的保护范围。
另外,需要注意的是,除非特别指明,下面实施例中所用的各种材料和试剂都是本领域中常用的材料和试剂,可以通过常规的商业途径获得;所用的中间体可以通过常规的商业途径获得或通过公知的方法制备;所用方法均为本领域技术人员公知的常规方法。
化学实施例
实施例1-2:固相合成胞壁酰二肽简化物MDA
实施例1:合成Fmoc-D-iso-Gln-OH
合成路线如下:
反应试剂与条件:(a)r.t.,3d;(b)DCC,0°C,5h,r.t,20h;(c)NH3;-10°C,1.5h.
步骤一:合成Fmoc-D-Glu-OH
将29.4g(1.0eq)D构型谷氨酸(H-D-Glu-OH)溶于丙酮-水混合溶液(体积比1:1)中,冰浴条件下搅拌;完全溶解后,少量多次地加入23.3g(1.1eq)NaHCO3,然后,缓缓加入67.4g(1.0eq)Fmoc-OSu,冰浴至室温搅拌3天;反应结束后,冰浴条件下,用2N盐酸将溶液体系的PH值调至2~3,减压蒸干反应体系中的丙酮溶液,残余液用乙酸乙酯萃取4次,合并乙酸乙酯层,无水硫酸镁干燥过夜,过滤,减压蒸干乙酸乙酯溶液,残余物用乙酸乙酯-环己烷重结晶,得到59.8g目标产物,产率81%。
步骤二:合成Fmoc-D-iso-Gln-OH
将59.8g(1.0eq)Fmoc-D-Glu-OH溶于无水324mL的无水四氢呋喃中(浓度=0.5mol/L),冰浴条件下搅拌,缓缓加入40.1g(1.2eq)DCC,冰浴条件下反应2小时,室温继续反应8小时。体系内析出大量白色沉淀(DCU),过滤,用少量四氢呋喃洗涤滤饼。滤液置于氯化钠冰盐浴内搅拌,同时向体系内通入干燥无水的氨气,15分钟后,体系内产生大量白色沉淀,继续反应1.5小时,体系内停止产生白色沉淀,反应结束。静置30分钟,向溶液体系内加入少量无水甲醇,白色沉淀迅速溶解,冰浴条件下,用2N盐酸将溶液体系的pH值调至2~3;减压蒸干溶剂,残余液用乙酸乙酯溶解稀释,依次用稀盐酸溶液,饱和碳酸氢钠溶液和水溶液萃取洗涤乙酸乙酯,分离乙酸乙酯相,无水硫酸镁干燥过夜,过滤,减压蒸干乙酸乙酯溶液,残余物用乙酸乙酯-环己烷重结晶,得到46.5g目标产物,产率78%,m.p.=204~205℃,[α]=-4.2°(C=10mg/mL,DMF)。
1H-NMR(500MHz,DMSO):7.88(2H,d,J=8.0Hz),7.72(2H,m),7.42(2H,m),7.40(1H,m),7.40(1H,br.s),7.32(2H,m,7.02(1H,br.s),4.27(2H,m),4.20(1H,m),3.93(1H,dd,J=13.5and8.5Hz),2.25(2H,m),1.89(1H,m),.1.73(1H,m).
13C-NMR(125MHz,DMSO):173.9,173.4,155.9,143.8,140.7,127.6,127.0,125.3,120.0,65.6,53.8,46.6,30.4,27.2.
ESI-MS:369.03[M+H]+,759.98[2M+Na]+.
HR-MS(TOF):369.1448[M+H]+,759.2623[2M+Na]+,C20H20N2O5.
实施例2:胞壁酰二肽简化物MDA的固相合成
合成路线如下:
反应试剂与条件:(a)20%piperidine/DMF;rt,1h;(b)Fmoc-Lys(Boc)-OH,HOBt,DIC;r.t,8h;(C)Fmoc-D-iso-Gln-OH,HOBt,DIC;r.t,12h;(d)Fmoc-Ala-OH,HOBt,DIC;r.t,8h;(e)4-chloro-cinnamic acid(R),HOBt,DIC;r.t,8h;(f)90%TFA/H2O,r.t.,2h.
将100g(0.88mmol/g,1.0eq)Rink-Amide AM树脂放入固相反应器,减压抽真空1小时后,加入500mL严格无水的二氯甲烷溶胀45分钟。抽干二氯甲烷溶剂,加入500mL含20%(体积比)哌啶的N,N-二甲基甲酰胺溶液,脱除树脂的Fmoc保护基,反应1小时后,抽干反应液,然后先后用500mL N,N-二甲基甲酰胺和二氯甲烷洗涤树脂6次,抽干溶剂;向反应器内加入61.8g(1.5eq)Fmoc-Lys(Boc)-
COOH,17.8g(1.5eq)HOBt,20.8mL(1.5eq)DIC及500mL N,N-二甲基甲酰胺溶剂,向树脂引入第一个氨基酸,反应8小时后,取少量树脂进行茚三酮法检测,树脂未呈现蓝色,阴性,说明反应完全,抽干反应液,加入500mL含20%(体积比)哌啶的N,N-二甲基甲酰胺溶液,脱除氨基酸的Fmoc保护基,反应1小时后,抽干反应液,然后先后用500mL N,N-二甲基甲酰胺和二氯甲烷洗涤树脂6次,抽干溶剂;向反应器内加入48.5g(1.5eq)Fmoc-D-iso-Gln-COOH,17.8g(1.5eq)HOBt,20.8mL(1.5eq)DIC及500mL N,N-二甲基甲酰胺溶剂,向树脂引入第二个氨基酸,反应12小时后,取少量树脂进行茚三酮法检测,树脂未呈现蓝色,阴性,说明反应完全,抽干反应液,加入500mL含20%(体积比)哌啶的N,N-二甲基甲酰胺溶液,脱除氨基酸的Fmoc保护基,反应1小时后,抽干反应液,然后先后用500mL N,N-二甲基甲酰胺和二氯甲烷洗涤树脂6次,抽干溶剂;向反应器内加入41.0g(1.5eq)Fmoc-Ala-COOH,17.8g(1.5eq)HOBt,20.8mL(1.5eq)DIC及500mL N,N-二甲基甲酰胺溶剂,向树脂引入第三个氨基酸,反应8小时后,取少量树脂进行茚三酮法检测,树脂未呈现蓝色,阴性,说明反应完全,抽干反应液,加入500mL含20%(体积比)哌啶的N,N-二甲基甲酰胺溶液,脱除氨基酸的Fmoc保护基,反应1小时后,抽干反应液,然后先后用500mL N,N-二甲基甲酰胺和二氯甲烷洗涤树脂6次,抽干溶剂;向反应器内加入24.1g(1.5eq)对氯肉桂 酸,17.8g(1.5eq)HOBt,20.8mL(1.5eq)DIC及500mL N,N-二甲基甲酰胺溶剂,向树脂引入第四个有机酸,反应8小时后,取少量树脂进行茚三酮法检测,树脂未呈现蓝色,阴性,说明反应完全,抽干反应液,然后先后用500mL N,N-二甲基甲酰胺和二氯甲烷洗涤树脂6次,抽干溶剂;加入90%(体积比)的三氟乙酸水溶液,裂解2小时,收集裂解液,然后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,收集裂解液,最后用200mL二氯甲烷洗涤树脂,滤液与裂解液合并,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,静置小时,取出上清液,继续加入无水乙醚研磨洗涤白色固体,反复多次,过滤,得到39.8g目标产物粗品,产率89%。将39.8g目标产物粗品经ODS柱层析,甲醇-水梯度洗脱纯化,将含目标产物的溶液合并,减压蒸干溶剂,冷冻干燥,得到35.8g纯度为98.5%的目标产物,m.p.=215~217℃,[α]=+37.7°(C=11.05mg/mL,DMF)。
1H-NMR(600MHz,DMSO-d6):7.47(2H,d,J=8.4Hz,2and6-H),7.57(2H,d,J=8.4Hz,3and5-H),7.39(1H,d,J=15.9Hz,7-H),6.75(1H,d,J=15.9Hz,8-H),8.39(1H,d,J=6.6Hz,10-H),4.38(1H,m,11-H),1.26(3H,m,12-H),8.21(1H,d,J=8.4Hz,14-H),4.14(1H,m,15-H),6.98(1H,s,17-Ha),7.41(1H,s,17-Hb),1.71(1H,m,18-Ha),1.97(1H,m,18-Hb),2.15(2H,t,J=7.2Hz,19-H),7.90(1H,d,J=8.4Hz,21-H),4.11(1H,m,22-H),7.10(1H,s,24-Ha),7.30(1H,s,24-Hb),1.46(1H,m,25-Ha),1.63(1H,m,25-Hb),1.27(2H,m,26-H),1.53(2H,m,27-H),2.73(2H,m,28-H),7.75(2H,br.s,29-H).
13C-NMR(150MHz,DMSO-d6):134.0(1-C),129.0(2and6-C),129.2(3and5-C),133.8(4-C),137.6(7-C),122.7(8-C),164.7(9-C),48.8(11-C),18.1(12-C),172.4(13-C),52.2(15-C),173.8(16-C),27.7(18-C),31.7(19-C),171.6(20-C),52.1(22-C),173.3(23-C),31.3(25-C),22.4(26-C),26.8(27-C),38.7(28-C).
IR:3282.3,3202.2(νOH and νNH),3067.3(ν=CH),2938.0(ν-CH),1609.5(ν-C=O),1537.5,1450.2(νC=C),1199.0,1180.2,1130.6(δ-CH),972.4,820.4,799.4,720.0(δ=CH andνC-Cl).
ESI-MS:509.60[M+H]+,1017.24[2M+H]+.
HR-MS(TOF):509.2292[M+H]+,C23H33ClN6O5.
实施例3-9:液相合成胞壁酰二肽简化物MDA
合成路线如下:
反应试剂与条件:(a)HOSu,DIC,NH3;-10°C,1.5h;(b)50%TFA/DCM;rt1h;(c)HOSu,DIC;0°C,5h,r.t.,20h;(d)0°C,5h,r.t.,24h;(e)HBr/HOAc;r.t.,3h;(f)BF3·Et2O,TFA,EtSH(9:9:2);r.t.2h.
实施例3:液相合成Boc-D-Glu(OBzl)-NH2
合成路线如下:
反应试剂与条件:(a)C6H5CH2OH,BF3·Et2O;r.t.,15h;(b)(Boc)2O,NaHCO3;r.t.,20h;(c)HOSu,DCC,NH3;-10°C,1.5h.
步骤一:液相合成H-D-Glu(OBzl)-OH
将29.1g(1.0eq)D构型谷氨酸(H-D-Glu-OH)溶于205.6mL(10.0eq)苯甲醇,室温搅拌,缓慢加入47.7mL(2.0eq)三氟化硼乙醚溶液,10分钟后,样品溶解。15小时后,反应结束,向反应体系内加入616.8mL(苯甲醇体积的3倍)的四氢呋喃,搅拌均匀,再缓慢加入55.1mL三乙胺溶液(2.0eq),反应体系内析出大量白色粘稠状沉淀,减压蒸干四氢呋喃,冷却后,加入适量乙酸乙酯,粘稠状沉淀呈现粉末状沉淀,过滤,充分抽干,得到36.6g目标产物,产率78%,m.p.=174~176℃。
步骤二:液相合成Boc-D-Glu(OBzl)-OH
将36.6g(1.0eq)H-D-Glu(OBzl)-OH溶于500mL二氧六环水溶液(体积比1:1)中,先 后加入67.3g(2.0eq)Boc酸酐和25.3g(2.0eq)碳酸氢钠,油浴加热助溶,样品完全溶解后,室温下反应20小时。反应结束后,减压蒸干二氧六环溶剂,得到大量白色粘稠状固体,用500mL水稀释助溶,搅拌30分钟,样品溶解。冰浴条件下,用2N盐酸将溶液体系的PH值调至2~3,体系内出现混浊,静置30分钟。然后,用乙酸乙酯萃取5次,分离并合并乙酸乙酯相,无水硫酸镁干燥过夜,过滤,减压蒸干乙酸乙酯溶液,得到48.6g目标产物(黄色油状物),产率96%。
步骤三:液相合成Boc-D-Glu(OBzl)-NH2
将48.6g(1.0eq)Boc-D-Glu(OBzl)-OH溶于四氢呋喃中,先后加入24.8g(1.5eq)HOSu和44.5g(1.5eq)DCC,冰浴条件下反应5小时,室温继续反应20小时。体系内析出大量白色沉淀(DCU),过滤,用少量四氢呋喃洗涤滤饼。滤液置于氯化钠冰盐浴内搅拌,同时向体系内通入干燥无水的氨气,15分钟后,体系内产生大量白色沉淀,继续反应1.5小时,体系内停止产生白色沉淀,反应结束。过滤,用少量四氢呋喃洗涤滤饼,减压蒸干四氢呋喃,得到黄色油状物,用适量乙酸乙酯溶解,冰浴条件下,用2N盐酸将溶液体系的pH值调至7,静置30分钟。然后依次用稀盐酸溶液,饱和碳酸氢钠溶液和水溶液萃取洗涤乙酸乙酯相,分离乙酸乙酯相,无水硫酸镁干燥过夜,过滤,减压蒸干乙酸乙酯溶液,残余物用乙酸乙酯-环己烷重结晶,得到34.2g目标产物,产率75%,m.p.=122~123℃,[α]=-1.8°(C=9.8mg/mL,DMF)。
1H-NMR(300MHz,DMSO-d6):1.36(9H,s,-C(CH3)3),6.82(1H,d,J=8.4Hz,4-H),3.86(1H,m,5-H),7.01(1H,s,7-Ha),7.31(1H,s,7-Hb),1.73(1H,m,8-Ha),1.88(1H,m,8-Hb),2.36(2H,t,J=7.2Hz,9-H),5.07(2H,s,11-H),7.25-7.39(5H,m,12~16-H).
13C-NMR(125MHz,DMSO-d6):28.1(1-C),78.0(2-C),155.3(3-C),53.3(5-C),173.5(6-C),27.1(8-C),30.2(9-C),172.2(10-C),65.4(11-C),127.8(12 and 16-C),128.4(13 and 15-C),127.9(14-C).
ESI-MS:337.75[M+H]+,673.32[2M+H]+.
HR-MS(TOF):337.1754[M+H]+,359.1572[M+Na]+,C17H24N2O5.
实施例4:液相合成Boc-Lys(Z)-NH2
将38.0g(1.0eq)Boc-Lys(Z)-OH溶于四氢呋喃中,先后加入13.8g(1.2eq)HOSu和18.9ml(1.2eq)DIC,冰浴条件下反应5小时,室温继续反应20小时。体系内析出大量白色沉淀(DIU),过滤,用少量四氢呋喃洗涤滤饼。滤液置于氯化钠冰盐浴内搅拌,同时向体系内通入干燥无 水的氨气,15分钟后,体系内产生大量白色沉淀,继续反应1.5小时,体系内停止产生白色沉淀,反应结束。过滤,用少量四氢呋喃洗涤滤饼,减压蒸干四氢呋喃,得到白色固体,用适量乙酸乙酯溶解,冰浴条件下,用2N盐酸将溶液体系的PH值调至7,静置30分钟。然后依次用稀盐酸溶液,饱和碳酸氢钠溶液和水溶液萃取洗涤乙酸乙酯,分离乙酸乙酯相,无水硫酸镁干燥过夜,过滤,减压蒸干乙酸乙酯溶液,残余物用乙酸乙酯-环己烷重结晶,得到35.0g目标产物,产率92%,m.p.=137~138℃。
1H-NMR(300MHz,DMSO-d6):1.37(9H,br.s,1-H),6.71(1H,d,J=8.1Hz,4-H),3.79(1H,m,5-H),7.23(2H,br.s,7-H),1.28(2H,m,8-H),1.45(2H,m,9-H),1.58(2H,m,10-H),2.95(2H,m,11-H),6.93(1H,br.s,12-H),5.00(2H,s,14-H),7.22-7.39(5H,m,16~20-H).
ESI-MS:380.71[M+H]+,759.50[2M+H]+.
HR-MS(TOF):380.2201[M+H]+,781.4102[2M+Na]+,C19H29N3O5.
实施例5:液相合成二肽片段Boc-Ala-D-Glu(OBzl)-NH2
将16.9g(1.0eq)Boc-Ala-OH溶于四氢呋喃中,先后加入12.3g(1.2eq)HOSu和16.9mL(1.2eq)DIC,冰浴条件下反应5小时,室温继续反应20小时。体系内析出大量白色沉淀(DIU),过滤,用少量四氢呋喃洗涤滤饼,滤液(Boc-Ala-OSu)待用。
将30g(1.0eq)Boc-D-Glu(OBzl)-NH2溶于100mL的三氟乙酸二氯甲烷溶液(体积比1:1),室温搅拌1小时,脱除Boc保护基。反应结束后,减压蒸干三氟乙酸,残余液用无水乙醚反复研磨、洗涤并蒸干,最后溶于少量四氢呋喃中,冰浴条件下用N-甲基吗啉(NMM)将溶液体系的pH值调至7~8。然后将Boc-Ala-OSu溶液少量多次地加入其中,冰浴条件下反应5小时,室温继续反应24小时。反应完全后,减压蒸干溶剂,残余物溶于适量乙酸乙酯中,依次用稀盐酸溶液,饱和碳酸氢钠溶液和水溶液萃取洗涤乙酸乙酯相,分离乙酸乙酯相,无水硫酸镁干燥过夜,过滤,减压蒸干乙酸乙酯溶液,残余物用甲醇-水重结晶,并用大量无水乙醚洗涤,得到29.4g目标产物,产率81%,m.p.=134~135℃。
1H-NMR(300MHz,DMSO-d6):1.36(9H,br.s,.1-H),7.92(1H,d,J=7.8Hz,4-H),4.17(1H,m,5-H),1.15(3H,d,J=7.2Hz,6-H),7.10(1H,d,J=6.6Hz,8-H),3.91(1H,m,9-H),7.18(1H,br.s,11-Ha),7.31(1H,br.s,11-Hb),1.75(1H,m,12-Ha),2.03(1H,m,12-Hb),2.33(2H,t,J=7.5Hz,13-H),5.07(2H,s,15-H),7.31-7.40(5H,m,17~21-H).
ESI-MS:408.71[M+H]+,815.44[2M+H]+.
HR-MS(TOF):408.2137[M+H]+,430.1955[M+Na]+,C20H29N3O6.
实施例6:液相合成三肽片段
将13.2g(1.0eq)对氯肉桂酸溶于四氢呋喃中,先后加入9.9g(1.2eq)HOSu和13.6mL(1.2eq)DIC,冰浴条件下反应5小时,室温继续反应20小时。体系内析出大量白色沉淀(DIU),过滤,用少量四氢呋喃洗涤滤饼,滤液(Ac-OSu)待用。
将29.4g(1.0eq)Boc-Ala-D-Glu(OBzl)-NH2溶于100mL的三氟乙酸二氯甲烷溶液(体积比1:1),室温搅拌1小时,脱除Boc保护基。反应结束后,减压蒸干三氟乙酸,残余液用无水乙醚反复研磨、洗涤并蒸干,最后溶于少量四氢呋喃中,冰浴条件下用N-甲基吗啉(NMM)将溶液体系PH值调至7~8。然后将Ac-OSu溶液少量多次地加入其中,冰浴条件下反应5小时,室温继续反应24小时,最后加热回流2小时。反应完全后,静置30分钟,体系内产生大量白色粘稠状沉淀,过滤,用少量四氢呋喃洗涤滤饼,抽干后,将所得固体溶于适量乙酸乙酯中,依次用稀盐酸溶液,饱和碳酸氢钠溶液和水溶液萃取洗涤有机相,分离乙酸乙酯相,无水硫酸镁干燥过夜,过滤,减压蒸干乙酸乙酯溶液,残余物用甲醇-水重结晶,并用大量无水乙醚洗涤,得到26.8g目标产物,产率79%,m.p.=226~228℃。
1H-NMR(300MHz,DMSO-d6):7.48(2H,d,J=8.7Hz,2~6-H),7.59(2H,d,J=8.7Hz,3~5-H),7.39(1H,d,J=15.9Hz,7-H),6.76(1H,d,J=15.9Hz,8-H),8.39(1H,d,J=6.6Hz,10-H),4.38(1H,m,11-H),1.23(3H,d,J=6.9Hz,12-H),8.25(1H,d,J=8.1Hz,14-H),4.18(1H,m,15-H),7.16(1H,br.s,17-Ha),7.31(1H,br.s,17-Hb),1.78(1H,m,18-Ha),2.05(1H,m,18-Hb),2.38(2H,m,19-H),5.07(2H,s,21-H),7.31-7.36(5H,m,23~27-H).
ESI-MS:472.33[M+H]+,943.17[2M+H]+.
HR-MS(TOF):472.1635[M+H]+,943.3174[2M+H]+,C24H26ClN3O5.
实施例7:液相合成三肽片段
将26.8g实施例7中合成的三肽片段溶于氢溴酸的醋酸溶液中,室温搅拌2小时,脱除Bzl保护基。反应结束后,将反应液倒入适量冰水中,用10%的NaOH溶液将上述溶液的pH值调至10~11,用乙酸乙酯萃取水相。然后,用10%的HCl溶液将水相的PH值调至2~3,再用乙酸乙酯溶剂萃取水相3次,合并乙酸乙酯相,用饱和的NaCl溶液洗涤,并用无水Na2SO4干燥;过滤、减压蒸干溶剂至少量残余液,加入乙醚,体内析出大量白色固体,过滤,干燥后称重得到18.5g产物。产率85%。
1H-NMR(300MHz,DMSO-d6):7.45(2H,d,J=8.1Hz,2~6-H),7.56(2H,d,J=8.1Hz,3~5-H),7.42(1H,d,J=15.3Hz,7-H),6.75(1H,d,J=15.3Hz,8-H),8.39(1H,d,J=6.6Hz,10-H), 4.37(1H,m,11-H),1.25(3H,d,J=6.6Hz,12-H),8.21(1H,d,J=8.1Hz,14-H),4.16(1H,m,15-H),7.11(1H,br.s,17-Ha),7.30(1H,br.s,17-Hb),1.72(1H,m,18-Ha),1.98(1H,m,18-Hb),2.22(2H,m,19-H),12.25(1H,br.s,21-H).
ESI-MS:382.17[M+H]+,785.04[2M+Na]+.
HR-MS(TOF):382.1171[M+H]+,785.2073[2M+Na]+,C17H20ClN3O5.
实施例8:液相合成四肽片段
将16.3g(1.0eq)实施例8中脱去Bzl保护的三肽片段溶于四氢呋喃中,先后加入5.9g(1.2eq)HOSu和8.1mL(1.2eq)DIC,冰浴条件下反应5小时,室温继续反应20小时。体系内析出大量白色沉淀(DIU),过滤,用少量四氢呋喃洗涤滤饼,滤液待用。
将16.2g(1.0eq)Boc-Lys(Z)-NH2溶于100mL的三氟乙酸二氯甲烷溶液(体积比1:1),室温搅拌1小时,脱除Boc保护基。反应结束后,减压蒸干三氟乙酸,残余液用无水乙醚反复研磨、洗涤并蒸干,最后溶于少量四氢呋喃中,冰浴条件下用N-甲基吗啉(NMM)将溶液体系pH值调至7~8。然后将上述滤液少量多次地加入其中,冰浴条件下反应5小时,室温继续反应24小时。反应体系内产生大量白色粘稠状沉淀,过滤,少量四氢呋喃洗涤滤饼,抽干后,得到14.6g目标产物,产率74%,m.p.=195~196℃。
1H-NMR(300MHz,DMSO-d6):7.47(2H,m,2and6-H),7.58(2H,m,3and5-H),7.38(1H,d,J=15.3Hz,7-H),6.79(1H,d,J=15.3Hz,8-H),8.45(1H,d,J=8.1Hz,10-H),4.40(1H,m,11-H),1.28(3H,m,12-H),8.29(1H,d,J=8.1Hz,14-H),4.19(1H,m,15-H),6.95(1H,s,17a-H),7.41(1H,s,17b-H),1.71(1H,m,18a-H),1.96(1H,m,18b-H),2.14(2H,m,19-H),7.92(1H,m,21-H),4.12(1H,m,22-H),7.09(1H,s,24a-H),7.33(1H,m,24b-H),1.49(1H,m,25a-H),1.65(1H,m,25b-H),1.27(2H,m,26-H),1.53(2H,m,27-H),2.91(2H,m,28-H),6.91(1H,br.s,29-H),5.00(2H,s,31-H),7.20-7.38(5H,m,33~37-H).
13C-NMR(125MHz,DMSO-d6):133.9(1-C),129.0(2and6-C),129.2(3and5-C),133.8(4-C),137.6(7-C),122.8(8-C),164.7(9-C),48.9(11-C),18.1(12-C),172.4(13-C),52.1(15-C),173.9(16-C),27.6(18-C),31.6(19-C),171.5(20-C),52.1(22-C),173.3(23-C),31.4(25-C),22.7(26-C),27.5(27-C),38.7(28-C),156.0(30-C),65.1(31-C),137.5(32-C),127.7(33 and 37-C),128.3(34 and 36-C),127.0(35-C).
ESI-MS:643.31[M+H]+.
HR-MS(TOF):643.2635[M+H]+,665.2451[M+Na]+,C31H39ClN6O7.
实施例9:液相合成胞壁酰二肽简化物MDA:
将14.6g实施例9中的四肽片段溶于三氟化硼乙醚、三氟乙酸和乙硫醇混合溶液(体积比9:9:2),室温下搅拌2小时,反应完全,减压蒸干溶剂,冰浴条件下向残余液中加入大量无水乙醚,析出白色固体沉淀,离心,取出上清液,再用大量无水乙醚反复研磨洗涤,得到8.3g目标产物粗品,产率72%。将8.3g目标产物粗品经ODS柱层析,甲醇-水梯度洗脱纯化,将含目标产物的溶液合并,减压蒸干溶剂,冷冻干燥,得到6.8纯度为98.5%的目标产物,m.p.=215~217℃,[α]=+37.7°(C=11.05mg/ml,DMF)。
1H-NMR(600MHz,DMSO-d6):7.47(2H,d,J=8.4Hz,2and6-H),7.57(2H,d,J=8.4Hz,3and5-H),7.39(1H,d,J=15.9Hz,7-H),6.75(1H,d,J=15.9Hz,8-H),8.39(1H,d,J=6.6Hz,10-H),4.38(1H,m,11-H),1.26(3H,m,12-H),8.21(1H,d,J=8.4Hz,14-H),4.14(1H,m,15-H),6.98(1H,s,17-Ha),7.41(1H,s,17-Hb),1.71(1H,m,18-Ha),1.97(1H,m,18-Hb),2.15(2H,t,J=7.2Hz,19-H),7.90(1H,d,J=8.4Hz,21-H),4.11(1H,m,22-H),7.10(1H,s,24-Ha),7.30(1H,s,24-Hb),1.46(1H,m,25-Ha),1.63(1H,m,25-Hb),1.27(2H,m,26-H),1.53(2H,m,27-H),2.73(2H,m,28-H),7.75(2H,br.s,29-H).
13C-NMR(150MHz,DMSO-d6):134.0(1-C),129.0(2and6-C),129.2(3and5-C),133.8(4-C),137.6(7-C),122.7(8-C),164.7(9-C),48.8(11-C),18.1(12-C),172.4(13-C),52.2(15-C),173.8(16-C),27.7(18-C),31.7(19-C),171.6(20-C),52.1(22-C),173.3(23-C),31.3(25-C),22.4(26-C),26.8(27-C),38.7(28-C).
IR:3282.3,3202.2(νOH andνNH),3067.3(ν=CH),2938.0(ν-CH),1609.5(ν-C=O),1537.5,1450.2(νC=C),1199.0,1180.2,1130.6(δ-CH),972.4,820.4,799.4,720.0(δ=CH andνC-Cl).
ESI-MS:509.60[M+H]+,1017.24[2M+H]+.
HR-MS(TOF):509.2292[M+H]+,C23H33ClN6O5.
实施例10-21:固相合成胞壁酰二肽简化物简化物
实施例10:固相合成胞壁酰二肽简化物MDA-201
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和对羟基肉桂酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压 蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率85%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体,m.p.=143~144℃。
1H-NMR(300MHz,DMSO-d6):9.94(1H,s,1-OH),6.79(2H,d,J=8.7Hz,2and6-H),7.59(2H,d,J=8.7Hz,3and5-H),7.36(1H,d,J=15.9Hz,7-H),6.51(1H,d,J=15.9Hz,8-H),8.25(1H,d,J=6.3Hz,10-H),4.34(1H,m,11-H),1.24(3H,m,12-H),8.17(1H,d,J=8.4Hz,14-H),4.12(1H,m,15-H),6.98(1H,s,17-Ha),7.31(1H,s,17-Hb),1.72(1H,m,18-Ha),1.98(1H,m,18-Hb),2.15(2H,m,19-H),7.89(1H,d,J=7.8Hz,21-H),4.11(1H,m,22-H),7.10(1H,s,24-Ha),7.31(1H,s,24-Hb),1.48(1H,m,25-Ha),1.63(1H,m,25-Hb),1.25(2H,m,26-H),1.50(2H,m,27-H),2.74(2H,m,28-H),7.76(2H,br.s,29-H).
13C-NMR(125MHz,DMSO-d6):159.0(1-C),115.8(2and6-C),129.3(3and5-C),125.8(4-C),139.2(7-C),118.2(8-C),165.5(9-C),48.9(11-C),17.9(12-C),172.6(13-C),52.2(15-C),173.8(16-C),27.6(18-C),31.7(19-C),171.6(20-C),52.1(22-C),173.3(23-C),31.3(25-C),22.4(26-C),26.7(27-C),38.7(28-C).
IR:3273.8,3194.6(νOH andνNH),3064.6(ν=CH),2943.4(ν-CH),1663.6(νC=O),1605.7,1537.3,1515.0,1450.4(νC=C),1201.6,1180.2,1135.7(δ-CH),983.8,835.0,800.4,721.6(δ=CH).
ESI-MS:491.39[M+H]+,981.21[2M+H]+.
HR-MS(TOF):491.2597[M+H]+,C23H34N6O6.
实施例11:固相合成胞壁酰二肽简化物MDA-202
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和对甲基肉桂酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率86%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体,m.p.=150~151℃。
1H-NMR(300MHz,DMSO-d6):2.30(3H,s,1-CH3),7.44(2H,d,J=8.1Hz,2and6-H),7.21(2H,d,J=8.1Hz,3and5-H),7.37(1H,d,J=15.9Hz,7-H),6.69(1H,d,J=15.9Hz,8-H),8.35(1H,d,J=6.6Hz,10-H),4.37(1H,m,11-H),1.25(3H,m,12-H),8.21(1H,d,J=8.1Hz,14-H),4.12(1H,m,15-H),6.99(1H,s,17-Ha),7.32(1H,s,17-Hb),1.73(1H,m,18-Ha),1.97(1H,m,18-Hb),2.16(2H,m,19-H),7.90(1H,d,J=7.8Hz,21-H),4.10(1H,m,22-H),7.11(1H,s,24-Ha),7.34(1H,s,24-Hb),1.49(1H,m,25-Ha),1.63(1H,m,25-Hb),1.28(2H,m,26-H),1.51(2H,m,27-H),2.74(2H,m,28-H),7.80(2H,br.s,29-H).
13C-NMR(125MHz,DMSO-d6):20.9(1-CH3),139.0(2and6-C),129.6(2and6-C),127.5(3and5-C),132.1(4-C),139.3(7-C),120.8(8-C),165.2(9-C),48.9(11-C),18.0(12-C),172.5(13-C),52.2(15-C),173.9(16-C),27.6(18-C),31.8(19-C),171.7(20-C),52.1(22-C),173.4(23-C),31.3(25-C),22.4(26-C),26.7(27-C),38.7(28-C).
IR:3278.8,3199.9(νOH andνNH),3063.3(ν=CH),2941.3(ν-CH),1656.3(νC=O),1540.7,1452.5(νC=C),1202.2,1184.1,1135.3(δ-CH),984.0,835.8,813.6,800.7,721.6(δ=CH).
ESI-MS:489.48[M+H]+,977.29[2M+H]+.
HR-MS(TOF):489.2819[M+H]+,C24H36N6O5.
实施例12:固相合成胞壁酰二肽简化物MDA-203
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和2,4-二氟肉桂酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率80%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体,m.p.=189~190℃。
1H-NMR(300MHz,DMSO-d6):7.35(1H,m,2-H),7.72(1H,dd,J=15.2and8.7Hz,5-H),7.18(1H,td,J=8.4and2.4Hz,6-H),7.44(1H,d,J=15.9Hz,7-H),6.82(1H,d,J=15.9Hz,8-H),8.51(1H,d,J=6.6Hz,10-H),4.40(1H,m,11-H),1.27(3H,d,J=7.2Hz,,12-H),8.24(1H,d,J=8.1Hz,14-H),4.17(1H,m,15-H),7.00(1H,s,17-Ha),7.33(1H,s,17-Hb),1.71(1H,m,18-Ha),1.97(1H,m,18-Hb),2.17(2H,t,J=7.8Hz,19-H),7.91(1H,d,J=8.4Hz,21-H),4.13(1H,m,22-H),7.07(1H,s,24-Ha),7.32(1H,s,24-Hb),1.49(1H,m,25-Ha),1.64(1H,m,25-Hb),1.29(2H,m,26-H),1.50(2H,m,27-H),2.75(2H,m,28-H).
13C-NMR(125MHz,DMSO-d6):163.7(m,1-C),104.7(t,J=26.0Hz,2-C),159.6(m,3-C),118.5(m,4-C),130.6(m,5-C),112.4(d,J=18.4Hz,6-C),137.4(s,7-C),124.3(s,8-C),164.7(s,9-C),48.9(11-C),18.0(12-C),172.2(13-C),52.1(15-C),173.2(16-C),27.6(18-C),31.7(19-C),171.6(20-C),52.0(22-C),172.3(23-C),31.3(25-C),22.4(26-C),26.8(27-C),38.7(28-C).
IR:3279.8,3198.2(νOH andνNH),3066.7(ν=CH),2939.5(ν-CH),1656.2(νC=O),1616.4,1544.6,1504.2,1454.1(νC=C),1202.1,1181.7,1138.8(νC-F andδ-CH),967.5,836.7,800.7,721.4(νC-Cl andδ=CH).
ESI-MS:511.28[M+H]+,1021.02[2M+H]+.
HR-MS(TOF):511.2482[M+H]+,C24H36N6O5.
实施例13:固相合成胞壁酰二肽简化物MDA-204
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和2-氟-4-氯肉桂酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率88%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体,m.p.=149~150℃。
1H-NMR(300MHz,DMSO-d6):7.54(1H,dd,J=10.8and1.8Hz,2-H),7.69(1H,t,J=8.7Hz,5-H),7.36(1H,dd,J=10.5and2.1Hz,6-H),7.44(1H,d,J=15.9Hz,7-H),6.87(1H,d,J=15.9Hz,8-H),8.57(1H,d,J=6.6Hz,10-H),4.40(1H,m,11-H),1.27(3H,d,J=7.2Hz,,12-H),8.27(1H,d,J=8.1Hz,14-H),4.13(1H,m,15-H),6.99(1H,s,17-Ha),7.35(1H,s,17-Hb),1.72(1H,m,18-Ha),1.98(1H,m,18-Hb),2.17(2H,t,J=7.8Hz,19-H),8.08(1H,d,J=8.1Hz,21-H),4.10(1H,m,22-H),7.12(1H,s,24-Ha),7.32(1H,s,24-Hb),1.49(1H,m,25-Ha),1.64(1H,m,25-Hb),1.29(2H,m,26-H),1.51(2H,m,27-H),2.74(2H,m,28-H).
13C-NMR(125MHz,DMSO-d6):135.1(d,J=10.9Hz,1-C),117.2(d,J=25.8Hz,2-C),160.7(d,J=252.5Hz,3-C),122.1(d,J=11.6Hz,4-C),130.8(s,5-C),125.9(d,J=3.0Hz,6-C),137.3(m,7-C),125.8(d,J=6.3Hz,8-C),164.6(s,9-C),49.4(11-C),18.5(12-C),172.8(13-C),52.7(15-C),174.3(16-C),28.1(18-C),32.2(19-C),172.1(20-C),52.6(22-C),173.8(23-C),31.8(25-C),22.9(26-C),27.5(27-C),38.7(28-C).
IR:3358.7,3284.3,3199.3(νOH andνNH),3067.3(ν=CH),2933.4(ν-CH),1654.7,1642.5,1642.5,1622.9(ν-C=O),1540.6,1489.9,1453.6(νC=C),1202.4,1129.9(νC-F andδ-CH),978.2,815.0,720.6,690.2(νC-Cl andδ=CH).
ESI-MS:527.49[M+H]+,1053.17[2M+H]+.
HR-MS(TOF):527.2192[M+H]+,C23H32ClFN6O5.
实施例14:固相合成胞壁酰二肽简化物MDA-205
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和2-氯-4-氟肉桂酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体, 过滤,得到目标产物粗品,产率86%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体,m.p.=137~138℃。
1H-NMR(300MHz,DMSO-d6):7.55(1H,dd,J=8.7and1.8Hz,2-H),7.77(1H,m,5-H),7.36(1H,m,6-H),7.66(1H,d,J=15.9Hz,7-H),6.79(1H,d,J=15.9Hz,8-H),8.47(1H,d,J=6.6Hz,10-H),4.42(1H,m,11-H),1.27(3H,d,J=6.9Hz,12-H),8.24(1H,d,J=8.4Hz,14-H),4.16(1H,m,15-H),7.00(1H,s,17-Ha),7.31(1H,s,17-Hb),1.72(1H,m,18-Ha),1.99(1H,m,18-Hb),2.17(2H,t,J=7.8Hz,19-H),7.91(1H,d,J=8.7Hz,21-H),4.13(1H,m,22-H),7.12(1H,s,24-Ha),7.33(1H,s,24-Hb),1.49(1H,m,25-Ha),1.65(1H,m,25-Hb),1.30(2H,m,26-H),1.52(2H,m,27-H),2.75(2H,br.s,28-H),7.79(2H,br.s,29-H).
13C-NMR(125MHz,DMSO-d6):162.7(d,J=250.0Hz,1-C),115.9(d,J=21.6Hz,2-C),134.6(d,J=10.0Hz,3-C),129.9(d,J=3.8Hz,4-C),129.7(d,J=10.0Hz,5-C),117.7(d,J=25.1Hz,3-C),137.5(7-C),125.4(8-C),164.8(9-C),49.3(11-C),18.6(12-C),172.1(13-C),52.6(15-C),174.2(16-C),28.2(18-C),32.2(19-C),172.1(20-C),52.5(22-C),173.7(23-C),31.8(25-C),22.9(26-C),27.2(27-C),38.2(28-C).
IR:3279.8(νOH andνNH),3066.0(ν=CH),2937.1(ν-CH),1776.1,1656.3(νC=O),1537.0,1489.0,1452.2(νC=C),1238.1,1201.1,1181.0,1135.6(νC-F andδ-CH),910.6,835.5,800.1,721.3(νC-Cl andδ=CH).
ESI-MS:527.28[M+H]+,1075.00[2M+Na]+.
HR-MS(TOF):527.2201[M+H]+,C23H32ClFN6O5.
实施例15:固相合成胞壁酰二肽简化物MDA-206
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和4-氟肉桂酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率92%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体,m.p.=218~220℃。
1H-NMR(300MHz,DMSO-d6):7.26(2H,t,J=8.7Hz,2and6-H),7.63(2H,dd,J=8.4and5.7Hz,3and5-H),7.42(1H,d,J=15.9Hz,7-H),6.71(1H,d,J=15.9Hz,8-H),8.37(1H,d,J=6.6Hz,10-H),4.40(1H,m,11-H),1.27(3H,d,J=7.2Hz,12-H),8.21(1H,d,J=8.1Hz,14-H),4.15(1H,m,15-H),7.00(1H,s,17-Ha),7.32(1H,s,17-Hb),1.71(1H,m,18-Ha),1.99(1H,m,18-Hb),2.17(2H,t,J=7.8Hz,19-H),7.90(1H,d,J=8.1Hz,21-H),4.14(1H,m,22-H),7.12(1H,s,24-Ha),7.32(1H,s,24-Hb),1.49(1H,m,25-Ha),1.64(1H,m,25-Hb),1.29(2H,m,26-H),1.52(2H,m,27-H),2.76(2H,m,28-H),7.71(2H,br.s,29-H).
13C-NMR(125MHz,DMSO-d6):163.2(d,J=245.8Hz,1-C),116.4(d,J=21.6Hz,2and6-C),130.1(d,J=8.5Hz,3and5-C),131.9(4-C),138.3(7-C),122.2(8-C),165.3(9-C),49.3(11-C),18.5(12-C),172.8(13-C),52.6(15-C),174.2(16-C),27.2(18-C),32.2(19-C),172.1(20-C),52.5(22-C),173.7(23-C),31.8(25-C),22.9(26-C),27.2(27-C),38.5(28-C).
IR:3278.5,3198.1(νOH andνNH),3068.1(ν=CH),2931.9(ν-CH),1672.8,1639.9(νC=O),1614.9,1539.4,1509.6,1451.7(νC=C),1201.7,1134.3(νC-F andδ-CH),971.4,831.4,800.6,721.0(δ=CH).
ESI-MS:493.25[M+H]+,1007.02[2M+Na]+.
HR-MS(TOF):493.2580[M+H]+,515.2381[M+Na]+,C23H33FN6O5.
实施例16:固相合成胞壁酰二肽简化物MDA-207
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和3-氟肉桂酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率75%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体,m.p.=195~196℃。
1H-NMR(300MHz,DMSO-d6):7.21(1H,s,2-H),7.38(1H,m,3-H),7.41(1H,m,5-H),7.47(1H,m,6-H),7.47(1H,d,J=15.9Hz,7-H),6.79(1H,d,J=15.9Hz,8-H),8.39(1H,d,J=6.0Hz,10-H),4.38(1H,m,11-H),1.26(3H,d,J=6.9Hz,12-H),8.22(1H,d,J=7.5Hz,14-H),4.13(1H,m,15-H),6.97(1H,s,17-Ha),7.30(1H,s,17-Hb),1.65(1H,m,18-Ha),1.97(1H,m,18-Hb),2.15(2H,m,19-H),7.90(1H,d,J=8.4Hz,21-H),4.13(1H,m,22-H),7.01(1H,s,24-Ha),7.30(1H,s,24-Hb),1.48(1H,m,25-Ha),1.65(1H,m,25-Hb),1.28(2H,m,26-H),1.48(2H,m,27-H),2.72(2H,m,28-H).
13C-NMR(125MHz,DMSO-d6):116.7(d,J=21.0Hz,1-C),162.9(d,J=242.3Hz,2-C),114.4(d,J=21.4Hz,3-C),137.9(d,J=7.8Hz,4-C),124.0(d,J=22.6Hz,5-C),131.4(6-C),138.1(7-C),124.0(8-C),165.1(9-C),49.3(11-C),18.6(12-C),172.8(13-C),52.6(15-C),174.3(16-C),28.2(18-C),32.2(19-C),172.0(20-C),52.5(22-C),173.7(23-C),31.8(25-C),22.9(26-C),27.2(27-C),38.5(28-C).
IR:3276.4,3201.1(νOH andνNH),3069.1(ν=CH),2938.1(ν-CH),1647.7(νC=O),1539.0,1448.0,1421.8(νC=C),1200.8,1180.2,1134.1(νC-F andδ-CH),972.1,834.9,798.7,721.2(δ=CH).
ESI-MS:493.25[M+H]+,1007.09[2M+Na]+.
HR-MS(TOF):493.2582[M+H]+,C23H33FN6O5.
实施例17:固相合成胞壁酰二肽简化物MDA-208
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和3,4-二氟肉桂酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率95%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体,m.p.=139~140℃。
1H-NMR(300MHz,DMSO-d6):7.66(1H,m,3-H),7.48(1H,m,5-H),7.45(1H,m,6-H),7.40(1H,d,J=15.9Hz,7-H),6.75(1H,d,J=15.9Hz,8-H),8.37(1H,d,J=6.9Hz,10-H),4.40(1H,m,11-H),1.27(3H,d,J=7.2Hz,,12-H),8.22(1H,d,J=7.8Hz,14-H),4.16(1H,m,15-H),700(1H,s,17-Ha),7.33(1H,s,17-Hb),1.71(1H,m,18-Ha),1.97(1H,m,18-Hb),2.17(2H,t,J=7.8Hz,19-H),7.90(1H,d,J=8.1Hz,21-H),4.13(1H,m,22-H),7.12(1H,s,24-Ha),7.31(1H,s,24-Hb),1.49(1H,m,25-Ha),1.65(1H,m,25-Hb),1.29(2H,m,26-H),1.52(2H,m,27-H),2.76(2H,m,28-H),7.73(2H,br.s,29-H).
13C-NMR(150MHz,DMSO-d6):149.3(dd,J=35.6and12.8Hz,1-C),151.2(dd,J=38.5and12.9Hz,2-C),118.6(d,J=17.5Hz,3-C),133.3(m,4-C),125.1(m,5-C),116.7(d,J=17.4Hz,6-C),137.3(s,7-C),123.8(s,8-C),165.0(9-C),49.3(11-C),18.6(12-C),172.8(13-C),52.6(15-C),174.3(16-C),28.2(18-C),31.8(19-C),172.1(20-C),52.5(22-C),173.7(23-C),31.8(25-C),22.9(26-C),27.2(27-C),38.2(28-C).
IR:3275.8,3196.4(νOH andνNH),3064.8(ν=CH),2938.1(ν-CH),1673.1(νC=O),1612.9,1542.1,1516.7,1451.5(νC=C),1201.6,1135.4(νC-F andδ-CH),969.3,834.3,800.6,721.2(δ=CH).
ESI-MS:511.30[M+H]+,1021.09[2M+H]+.
HR-MS(TOF):511.2479[M+H]+,C23H32F2N6O5.
实施例18:固相合成胞壁酰二肽简化物MDA-113
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和2-喹啉羧酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤, 得到目标产物粗品,产率80%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体MDA-113。
实施例19:固相合成胞壁酰二肽简化物MDA-119
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和2-噻吩基丙烯酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率83%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体MDA-119。
实施例20:固相合成胞壁酰二肽简化物MDA-130
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和2-硝基-4-氯苯甲酸,完成缩合反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率81%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体MDA-130。
实施例21:固相合成胞壁酰二肽简化物MDA-133
采用固相合成策略,选用Rink-Amide AM树脂(负载量0.88mmol/g),先后向树脂上引入Fmoc-Lys(Boc)-COOH,Fmoc-D-iso-Gln-COOH,Fmoc-Ala-COOH和2-萘氧基乙酸,完成缩合 反应,充分洗涤抽干树脂,最后用90%(体积比)的三氟乙酸水溶液继续裂解1小时,减压蒸干溶剂,冰浴条件下,向少量残余液中加入大量无水乙醚,体系内立刻析出白色固体,过滤,得到目标产物粗品,产率88%。粗品经ODS柱层析,冷冻干燥后,得到纯度为98.5%的白色固体MDA-133。
实施例22:液相合成多西紫杉醇2′-O-丁二酸单酯
合成路线如下:
反应试剂与条件:succinic anhydride,DMAP,r.t.,2h.
将8.07g(1.0eq)多西紫杉醇,1.2g(1.2eq)丁二酸酐和0.61g(0.5eq)DMAP溶于DMF中,室温搅拌2小时,反应完毕;然后,先后以DCM稀释DMF溶液,以2N盐酸水溶液洗涤DCM相3次,再以水洗涤DCM相一次;最后,分离DCM相,减压浓缩溶剂,向少量残余液中加入大量水,体系内析出白色固体,过滤,冷冻干燥,得到7.9g目标产物,产率87%,m.p.=181~182℃。
1H-NMR(600MHz,DMSO-d6):4.43(1H,br.s,1-OH),5.39(1H,d,J=7.2Hz,2-H),3.62(1H,d,J=7.2Hz,3-H),4.89(1H,d,J=9.6Hz,5-H),1.62(1H,m,6-Ha),2.22(1H,d,J=9.6Hz,6-Hb),4.04(1H,m,7-H),5.09(1H,s,10-H),5.77(1H,t,J=9.0Hz,13-H),1.62(1H,m,14-Ha),1.85(1H,dd,J=15.0and9.0Hz,14-Hb),0.97(3H,s,16-H),0.99(3H,s,17-H),1.73(3H,s,18-H),1.51(3H,s,19-H),3.98(1H,d,J=9.0Hz,20-Ha),4.02(1H,d,J=9.0Hz,20-Hb),2.26(3H,s,4-OCOCH3),5.06(1H,m,2-H),5.07(1H,m,3-H),7.86(1H,d,J=8.4Hz,3-NH),7.35(2H,d,J=7.8Hz,ph-o-H),7.40(2H,t,J=7.8Hz,ph-m-H),7.17(1H,t,J=7.8Hz,ph-p-H),7.97(2H,d,J=7.8Hz,OBz-o-H),7.63(2H,d,J=7.8Hz,OBz-m-H),7.71(1H,d,J=7.8Hz,OBz-p-H),1.37(9H,s,-C(CH3)3),2.50(2H,m,-CH 2 -CH2-COOH),2.60(2H,m-CH2-CH 2 -COOH),12.23(1H,br.s,-CH2-CH2-COOH).
13C-NMR(150MHz,DMSO-d6):76.8(1-C),74.8(2-C),46.0(3-C),80.3(4-C),83.7(5-C),36.5(6-C),70.8(7-C),56.9(8-C),209.3(9-C),73.7(10-C),135.9(11-C),136.8(12-C),71.7(13-C),34.7(14-C),42.9(15-C),26.4(16-C),20.8(17-C),13.7(18-C),9.8(19-C),75.4(20-C),165.3(2-OCO),169.5,22.5(4-OCOCH3),168.3(1′-C),75.1(2′-C),57.4(3′-C),155.2(3′-NHCO),78.5,28.1(-C(CH3)3),137.4(ph-q-C),127.4(ph-o-C),128.5(ph-m-C),128.0(ph-p-C),130.0(OBz-q-C),129.5(OBz-o-C),128.7(OBz-m-C),133.4(OBz-p-C),171.5,28.4,28.5,172.9(-CO-CH2-CH2-COOH).
ESI-MS:930.31[M+Na]+.
HR-MS(TOF):930.3507[M+Na]+,C47H57NO17.
实施例23:液相合成共缀物MDC-400
将90.7mg(1.0eq)多西紫杉醇2′-O-丁二酸单酯、11.5mg(1.0eq)HOSu和19.2mg(1.0eq)EDC·HCl溶于二甲基亚砜中,室温反应4小时;然后将50.8mg(1.0eq)胞壁酰二肽简化物MDA少量多次地加入二甲基亚砜中,用N-甲基吗啉将反应体系pH值调节至7~8,继续反应4小时。反应完全后,向反应体系内加入大量水,体系内析出白色固体,过滤,得到目标产物粗品,经ODS柱层析纯化,冷冻干燥,得到124mg固体,产率89%,m.p.=180~181℃。
1H-NMR(600MHz,DMSO-d6):4.41(1H,br.s,1-OH),5.39(1H,d,J=6.6Hz,2-H),3.62(1H,d,J=6.6Hz,3-H),4.89(1H,d,J=10.2Hz,5-H),1.66(1H,m,6-Ha),2.26(1H,m,6-Hb),4.04(1H,m,7-H),5.07(1H,s,10-H),5.77(1H,t,J=9.0Hz,13-H),1.64(1H,m,14-Ha),1.82(1H,dd,J=15.6and9.0Hz,14-Hb),0.96(3H,s,16-H),0.97(3H,s,17-H),1.68(3H,s,18-H),1.50(3H,s,19-H),3.99(1H,m,20-Ha),4.01(1H,d,J=9.0Hz,20-Hb),2.22(3H,s,4-OCOCH3),5.04(1H,m,2-H),5.06(1H,m,3-H),7.86(1H,m,3-NH),7.30(2H,m,ph-o-H),7.35(2H,d,J=7.8Hz,ph-m-H),7.16(1H,t,J=7.2Hz,ph-p-H),7.97(2H,d,J=7.8Hz,OBz-o-H),7.64(2H,t,J=7.8Hz,OBz-m-H),7.71(1H,t,J=7.2Hz,OBz-p-H),1.36(9H,s,-C(CH3)3),2.59(2H,m,22-H),2.36(2H,m,23-H),7.83(1H,m,25-H),2.92(1H,m,26-Ha),3.00(1H,m,26-Hb),1.21(2H,m,27-H),1.27(2H,m,28-H),1.52(1H,m,29-Ha),1.63(1H,m,29-Hb),4.11(1H,m,30-H),6.96(1H,s,32-Ha),7.30(1H,s,32-Hb),7.90(1H,m,33-H),2.15(2H,m,35-H),1.72(1H,m,36-Ha),1.99(1H,m,36-Hb),4.13(1H,m,37-H),7.02(1H,s,39-Ha),7.30(1H,s,39-Hb),8.29(1H,m,40-H),4.38(1H,m,42-H),1.26(3H,d,J=6.6Hz,43-H),8.38(1H,d,J=6.6Hz,44-H),6.75(1H,d,J=16.2Hz,46-H),7.37(1H,d,J=16.3Hz,47-H),7.57(2H,d,J=8.4Hz,49and53-H),7.46(2H,d,J=8.4Hz,50and52-H).
13C-NMR(150MHz,DMSO-d6):76.8(1-C),74.8(2-C),46.1(3-C),80.3(4-C),83.7(5-C),36.5(6-C),70.7(7-C),57.0(8-C),209.3(9-C),73.7(10-C),136.0(11-C),136.8(12-C),71.1(13-C),34.7(14-C),42.9(15-C),26.5(16-C),20.8(17-C),13.6(18-C),9.8(19-C),75.3(20-C),165.3(2-OCO),169.6,22.5(4-OCOCH3),168.9(1′-C),75.0(2′-C),55.1(3′-C),155.2(3′-NHCO),78.5,28.1(-C(CH3)3),137.5(ph-q-C),127.4(ph-o-C),128.5(ph-m-C),128.0(ph-p-C),130.0(OBz-q-C),129.6(OBz-o-C),128.7(OBz-m-C),133.4(OBz-p-C),171.9(21-C),28.9(22-C),29.6(23-C),170.0(24-C),38.5(26-C),28.9(27-C),23.0(28-C),31.4(29-C),52.1(30-C),174.1(31-C),171.6(34-C),31.7(35-C),27.7(36-C),52.4(37-C),173.4(38-C),172.3(41-C),48.8(42-C),18.1(43-C),164.7(45-C),122.7(46-C),137.6(47-C),133.8(48-C),129.0(49and53-C),129.2(50and52-C),134.0(51-C).
IR:3320.6(νOH andνNH),2976.8,2933.5(ν-CH),1739.7,1658.6(νC=O),1531.5,1496.5,1452.4(νC=C),1246.2(νC-O-C),983.5,707.9(δ=CH).
ESI-MS:1398.14[M+H]+,1420.32[2M+Na]+.
HR-MS(TOF):1398.5791[M+H]+,1420.5609[M+Na]+,C70H88ClN7O21.
实施例24:液相合成共缀物MDC-403
将90.7mg(1.0eq)多西紫杉醇2′-O-丁二酸单酯、11.5mg(1.0eq)HOSu和19.2mg(1.0eq)EDC·HCl溶于二甲基亚砜中,室温反应4小时;然后将51mg(1.0eq)胞壁酰二肽简化物MDA-203少量多次地加入二甲基亚砜中,用N-甲基吗啉将反应体系pH值调节至7~8,继续反应4小时。反应完全后,向反应体系内加入大量水,体系内析出白色固体,过滤,得到目标产物粗品,经ODS柱层析纯化,冷冻干燥,得到114mg固体,产率80%,m.p.=165~166℃。
1H-NMR(500MHz,DMSO-d6):4.45(1H,br.s,1-OH),5.44(1H,d,J=6.0Hz,2-H),3.64(1H,d,J=6.0Hz,3-H),4.89(1H,m,5-H),1.66(1H,m,6-Ha),2.25(1H,m,6-Hb),4.03(1H,m,7-H),5.09(1H,s,10-H),5.80(1H,m,13-H),1.64(1H,m,14-Ha),1.82(1H,m,14-Hb),0.96(3H,s,16-H),0.96(3H,s,17-H),1.68(3H,s,18-H),1.52(3H,s,19-H),3.99(1H,m,20-Ha),4.01(1H,m,20-Hb),2.22(3H,s,4-OCOCH3),5.04(1H,m,2′-H),5.06(1H,m,3′-H),7.86(1H,m,3′-NH),7.31(2H,m,ph-o-H),7.38(2H,m,ph-m-H),7.19(1H,m,ph-p-H),7.99(2H,d,J=6.5Hz,OBz-o-H),7.66(2H,m,OBz-m-H),7.72(1H,m,OBz-p-H),1.39(9H,s,-C(CH3)3),2.62(2H,m,22-H),2.39(2H,m,23-H),7.83(1H,m,25-H),3.01(2H,br.s,26-H),1.21(2H,m,27-H),1.29(2H,m,28-H),1.52(1H,br.s,29-Ha),1.63(1H,br.s,29-Hb),4.14(1H,m,30-H),6.96(1H,s,32-Ha),7.31(1H,s,32-Hb),7.90(1H,m,33-H),2.17(2H,m,35-H),1.70(1H,m,36-Ha),1.99(1H,m,36-Hb),4.13(1H,m,37-H),7.02(1H,s,39-Ha),7.30(1H,s,39-Hb),8.22(1H,m,40-H),4.38(1H,m,42-H),1.26(3H,m,43-H),8.47(1H,d,J=6.0Hz,44-H),6.82(1H,d,J=16.0Hz,46-H),7.37(1H,m,47-H),7.18(1H,m,51-H),7.70(1H,m,53-H).
13C-NMR(125MHz,DMSO-d6):77.2(1-C),75.2(2-C),46.4(3-C),80.8(4-C),84.2(5-C),36.9(6-C),71.2(7-C),57.4(8-C),209.3(9-C),74.2(10-C),136.0(11-C),136.8(12-C),71.2(13-C),35.2(14-C),43.3(15-C),26.9(16-C),21.2(17-C),14.1(18-C),10.3(19-C),75.3(20-C),165.1(2-OCO),170.5,22.9(4-OCOCH3),168.9(1′-C),75.0(2′-C),55.6(3′-C),155.2(3′-NHCO),79.0,28.1(-C(CH3)3),137.5(ph-q-C),127.9(ph-o-C),128.5(ph-m-C),128.0(ph-p-C),130.0(OBz-q-C),129.2(OBz-o-C),128.7(OBz-m-C),133.4(OBz-p-C),172.0(21-C),28.6(22-C),29.3(23-C),170.0(24-C),39.0(26-C),28.6(27-C),23.4(28-C),31.4(29-C),52.1(30-C),174.1(31-C),171.6(34-C),31.7(35-C),27.7(36-C), 52.6(37-C),173.7(38-C),172.3(41-C),49.4(42-C),18.5(43-C),164.7(45-C),122.7(46-C),137.6(47-C),118.5(m,48-C),161.7(m,49-C),104.6(m,50-C),163.7(m,51-C),112.4(m,52-C),130.5(m,53-C).
IR:3323.9(νOH andνNH),2977.6,2937.6(ν-CH),1739.5,1659.3(νC=O),1532.5,1504.2,1452.5(νC=C),1368.2,1272.7,1246.8,1161.2,1069.2(δ-CH),983.0,852.5,708.8(δ=CH).
ESI-MS:1400.98[M+H]+,1422.43[M+Na]+.
HR-MS(TOF):1400.6008[M+H]+,1422.5824[M+Na]+,C70H87F2N7O21.
实施例25:液相合成共缀物MDC-404
将90.7mg(1.0eq)多西紫杉醇2′-O-丁二酸单酯、11.5mg(1.0eq)HOSu和19.2mg(1.0eq)EDC·HCl溶于二甲基亚砜中,室温反应4小时;然后将52.6mg(1.0eq)胞壁酰二肽简化物MDA-204少量多次地加入二甲基亚砜中,用N-甲基吗啉将反应体系PH值调节至7~8,继续反应4小时。反应完全后,向反应体系内加入大量水,体系内析出白色固体,过滤,得到目标产物粗品,经ODS柱层析纯化,冷冻干燥,得到116mg固体,产率82%,m.p.=175~176℃。
1H-NMR(500MHz,DMSO-d6):4.42(1H,br.s,1-OH),5.41(1H,d,J=7.0Hz,2-H),3.65(1H,d,J=7.0Hz,3-H),4.90(1H,m,5-H),1.63(1H,m,6-Ha),2.28(1H,m,6-Hb),4.05(1H,m,7-H),5.09(1H,s,10-H),5.78(1H,t,J=8.5Hz,13-H),1.63(1H,m,14-Ha),1.83(1H,m,14-Hb),0.99(3H,s,16-H),1.02(3H,s,17-H),1.68(3H,s,18-H),1.51(3H,s,19-H),4.00(1H,m,20-Ha),4.02(1H,m,20-Hb),2.23(3H,s,4-OCOCH3),5.02(1H,m,2′-H),5.09(1H,m,3′-H),7.86(1H,m,3′-NH),7.30(2H,m,ph-o-H),7.37(2H,m,ph-m-H),7.18(1H,m,ph-p-H),7.99(2H,d,J=7.5Hz,OBz-o-H),7.65(2H,m,OBz-m-H),7.71(1H,m,OBz-p-H),1.36(9H,s,-C(CH3)3),2.61(2H,m,22-H),2.37(2H,m,23-H),7.83(1H,m,25-H),3.00(1H,m,26-Ha),3.01(1H,m,26-Hb),1.20(2H,m,27-H),1.29(2H,m,28-H),1.52(1H,m,29-Ha),1.63(1H,m,29-Hb),4.11(1H,m,30-H),6.96(1H,s,32-Ha),7.30(1H,s,32-Hb),7.88(1H,m,33-H),2.16(2H,m,35-H),1.74(1H,m,36-Ha),2.00(1H,m,36-Hb),4.13(1H,m,37-H),7.01(1H,s,39-Ha),7.30(1H,s,39-Hb),8.24(1H,d,J=8.5Hz,40-H),4.40(1H,m,42-H),1.28(3H,m,43-H),8.51(1H,d,J=7.0Hz,44-H),6.86(1H,d,J=16.0Hz,46-H),7.38(1H,d,J=16.0Hz,47-H),7.54(1H,dd,J=11.0and2.0Hz,50-H),7.37(1H,m,52-H),7.71(1H,m,53-H).
13C-NMR(125MHz,DMSO-d6):76.8(1-C),75.3(2-C),46.4(3-C),80.8(4-C),84.2(5-C),36.9(6-C),71.2(7-C),57.4(8-C),209.8(9-C),74.2(10-C),136.5(11-C),137.3(12-C),71.5(13-C),35.2(14-C),42.6(15-C),26.9(16-C),21.3(17-C),14.1(18-C),10.3(19-C),75.5(20-C),165.7(2-OCO),169.4,23.4(4-OCOCH3),168.9(1′-C),75.3(2′-C),55.6(3′-C),155.7(3′-NHCO),79.0,28.2(-C(CH3)3), 137.3(ph-q-C),127.4(ph-o-C),128.4(ph-m-C),128.0(ph-p-C),130.8(OBz-q-C),129.0(OBz-o-C),128.4(OBz-m-C),133.7(OBz-p-C),172.0(21-C),28.9(22-C),29.3(23-C),170.0(24-C),38.5(26-C),28.6(27-C),22.9(28-C),32.1(29-C),52.7(30-C),174.4(31-C),172.0(34-C),32.2(35-C),28.1(36-C),52.8(37-C),173.6(38-C),172.3(41-C),49.4(42-C),18.5(43-C),164.9(45-C),122.2(46-C),138.0(47-C),122.1(d,J=11.8Hz,48-C),160.7(d,J=252.5Hz,49-C),117.3(d,J=28.8Hz,50-C),130.3(d,J=10.9Hz,51-C),125.2(s,52-C),130.4(s,53-C).
IR:3324.6(νOH andνNH),2977.0,2935.8(ν-CH),1739.5,1660.5(νC=O),1533.3,1452.6(νC=C),1368.2,1269.0,1248.3,1162.0,1070.6(δ-CH),984.2,856.3,708.8(δ=CH).
ESI-MS:1416.05[M+H]+,1438.05[M+Na]+.
HR-MS(TOF):1416.5693[M+H]+,1438.5511[M+Na]+,C70H87ClFN7O21.
实施例26:液相合成共缀物MDC-405
将90.7mg(1.0eq)多西紫杉醇2′-O-丁二酸单酯、11.5mg(1.0eq)HOSu和19.2mg(1.0eq)EDC·HCl溶于二甲基亚砜中,室温反应4小时;然后将52.6mg(1.0eq)胞壁酰二肽简化物MDA-205少量多次地加入二甲基亚砜中,用N-甲基吗啉将反应体系pH值调节至7~8,继续反应4小时。反应完全后,向反应体系内加入大量水,体系内析出白色固体,过滤,得到目标产物粗品,经ODS柱层析纯化,冷冻干燥,得到99mg固体,产率70%,m.p.=174~175℃。
1H-NMR(500MHz,DMSO-d6):4.42(1H,br.s,1-OH),5.41(1H,d,J=7.0Hz,2-H),3.65(1H,d,J=7.0Hz,3-H),4.90(1H,m,5-H),1.64(1H,m,6-Ha),2.28(1H,m,6-Hb),4.05(1H,m,7-H),5.09(1H,s,10-H),5.80(1H,t,J=8.5Hz,13-H),1.63(1H,m,14-Ha),1.83(1H,m,14-Hb),0.99(3H,s,16-H),1.02(3H,s,17-H),1.70(3H,s,18-H),1.51(3H,s,19-H),4.00(1H,m,20-Ha),4.02(1H,m,20-Hb),2.25(3H,s,4-OCOCH3),5.09(1H,m,2′-H),5.09(1H,m,3′-H),7.86(1H,m,3′-NH),7.31(2H,m,ph-o-H),7.35(2H,m,ph-m-H),7.19(1H,t,J=7.0Hz,ph-p-H),8.00(2H,d,J=7.5Hz,OBz-o-H),7.65(2H,m,OBz-m-H),7.71(1H,m,OBz-p-H),1.36(9H,s,-C(CH3)3),2.59(2H,m,22-H),2.36(2H,m,23-H),7.87(1H,m,25-H),3.00(1H,m,26-Ha),3.01(1H,m,26-Hb),1.20(2H,m,27-H),1.29(2H,m,28-H),1.52(1H,m,29-Ha),1.63(1H,m,29-Hb),4.11(1H,m,30-H),6.97(1H,s,32-Ha),7.32(1H,s,32-Hb),7.88(1H,m,33-H),2.16(2H,m,35-H),1.72(1H,m,36-Ha),1.99(1H,m,36-Hb),4.13(1H,m,37-H),7.11(1H,s,39-Ha),7.31(1H,s,39-Hb),8.25(1H,d,J=8.0Hz,40-H),4.38(1H,m,42-H),1.26(3H,m,43-H),8.45(1H,d,J=7.0Hz,44-H),6.79(1H,d,J=16.0Hz,46-H),7.38(1H,d,J=16.0Hz,47-H),7.56(1H,dd,J=9.0and3.0Hz,50-H),7.33(1H,m,52-H),7.75(1H,m,53-H).
13C-NMR(125MHz,DMSO-d6):77.3(1-C),75.3(2-C),46.4(3-C),80.8(4-C),84.2(5-C),36.9(6-C),71.2(7-C),57.0(8-C),209.3(9-C),74.2(10-C),136.5(11-C),137.3(12-C),71.6(13-C),35.2(14-C),43.3(15-C),26.9(16-C),21.2(17-C),14.1(18-C),10.3(19-C),75.9(20-C),165.7(2-OCO),170.0,22.9(4-OCOCH3),169.4(1′-C),75.5(2′-C),55.5(3′-C),155.7(3′-NHCO),78.9,28.2(-C(CH3)3),137.3(ph-q-C),127.9(ph-o-C),129.0(ph-m-C),129.1(ph-p-C),130.5(OBz-q-C),130.0(OBz-o-C),129.1(OBz-m-C),133.6(OBz-p-C),172.0(21-C),29.3(22-C),30.1(23-C),170.4(24-C),38.5(26-C),28.6(27-C),23.4(28-C),32.1(29-C),52.6(30-C),174.4(31-C),172.3(34-C),32.2(35-C),26.9(36-C),52.8(37-C),173.7(38-C),172.7(41-C),49.3(42-C),18.7(43-C),164.7(45-C),125.4(46-C),133.9(47-C),129.2(48-C),134.6(49-C),115.8(d,J=21.6Hz,50-C),162.7(d,J=249.6Hz,51-C),117.6(d,J=24.9Hz,52-C),129.6(53-C).
IR:3316.8(νOH andνNH),2977.3,2938.6(ν-CH),1739.5,1659.2(νC=O),1533.0,1490.7(νC=C),1368.3,1241.6,1161.7,1068.6(δ-CH),982.1,858.0,708.6(δ=CH).
ESI-MS:1416.52[M+H]+,1438.42[M+Na]+.
HR-MS(TOF):1416.5725[M+H]+,1438.5523[M+Na]+,C70H87ClFN7O21.
实施例27:液相合成共缀物MDC-406
将90.7mg(1.0eq)多西紫杉醇2′-O-丁二酸单酯、11.5mg(1.0eq)HOSu和19.2mg(1.0eq)EDC·HCl溶于二甲基亚砜中,室温反应4小时;然后将49.2mg(1.0eq)胞壁酰二肽简化物MDA-206少量多次地加入二甲基亚砜中,用N-甲基吗啉将反应体系PH值调节至7~8,继续反应4小时。反应完全后,向反应体系内加入大量水,体系内析出白色固体,过滤,得到目标产物粗品,经ODS柱层析纯化,冷冻干燥,得到125.6mg固体,产率91%,m.p.=162~163℃。
1H-NMR(500MHz,DMSO-d6):4.41(1H,br.s,1-OH),5.42(1H,d,J=7.0Hz,2-H),3.65(1H,d,J=7.0Hz,3-H),4.90(1H,m,5-H),1.66(1H,m,6-Ha),2.25(1H,m,6-Hb),4.03(1H,m,7-H),5.09(1H,s,10-H),5.80(1H,t,J=8.5Hz,13-H),1.64(1H,m,14-Ha),1.82(1H,m,14-Hb),0.99(3H,s,16-H),0.99(3H,s,17-H),1.68(3H,s,18-H),1.50(3H,s,19-H),3.99(1H,m,20-Ha),4.01(1H,m,20-Hb),2.22(3H,s,4-OCOCH3),5.09(1H,m,2′-H),5.09(1H,m,3′-H),7.86(1H,m,3′-NH),7.30(2H,m,ph-o-H),7.35(2H,m,ph-m-H),7.16(1H,t,J=7.0Hz,ph-p-H),7.99(2H,d,J=7.5Hz,OBz-o-H),7.65(2H,m,OBz-m-H),7.71(1H,m,OBz-p-H),1.36(9H,s,-C(CH3)3),2.55(2H,m,22-H),2.34(2H,m,23-H),7.83(1H,m,25-H),3.01(2H,br.s,26-H),1.21(2H,m,27-H),1.27(2H,m,28-H),1.52(1H,m,29-Ha),1.64(1H,m,29-Hb),4.11(1H,m,30-H),6.97(1H,s,32-Ha),7.31(1H,s,32-Hb),7.86(1H, m,33-H),2.17(2H,m,35-H),1.79(1H,m,36-Ha),2.00(1H,m,36-Hb),4.15(1H,m,37-H),7.11(1H,s,39-Ha),7.31(1H,s,39-Hb),8.22(1H,d,J=8.0Hz,40-H),4.38(1H,m,42-H),1.26(3H,m,43-H),8.35(1H,d,J=8.0Hz,44-H),6.71(1H,d,J=16.0Hz,46-H),7.38(1H,d,J=16.0Hz,47-H),7.87(2H,m,49an53-H),7.38(2H,m,50snd52-H).
13C-NMR(125MHz,DMSO-d6):77.3(1-C),75.3(2-C),46.4(3-C),80.7(4-C),84.2(5-C),36.9(6-C),71.2(7-C),57.4(8-C),209.8(9-C),74.2(10-C),136.5(11-C),137.2(12-C),71.6(13-C),35.1(14-C),43.3(15-C),26.9(16-C),21.2(17-C),14.1(18-C),10.3(19-C),75.9(20-C),165.8(2-OCO),170.0,22.9(4-OCOCH3),169.4(1′-C),75.5(2′-C),55.5(3′-C),155.7(3′-NHCO),79.0,28.5(-C(CH3)3),137.9(ph-q-C),127.9(ph-o-C),129.2(ph-m-C),128.5(ph-p-C),130.5(OBz-q-C),130.1(OBz-o-C),129.3(OBz-m-C),133.6(OBz-p-C),172.3(21-C),29.3(22-C),30.0(23-C),170.5(24-C),38.7(26-C),29.2(27-C),23.4(28-C),32.1(29-C),52.6(30-C),174.4(31-C),172.0(34-C),32.2(35-C),28.2(36-C),52.8(37-C),173.7(38-C),172.8(41-C),49.3(42-C),18.6(43-C),165.3(45-C),122.3(46-C),137.9(47-C),133.9(48-C),131.9(m,49and53-C),116.4(d,J=21.8Hz,50and52-C),163.2(d,J=245.3Hz,51-C).
IR:3318.8(νOH andνNH),2977.6,2938.0(ν-CH),1659.3(νC=O),1535.1,1511.9,1452.6(νC=C),1368.5,1246.7,1160.7,1069.1(δ-CH),983.0,832.9,708.1(δ=CH).
ESI-MS:1382.00[M+H]+,1404.60[M+Na]+.
HR-MS(TOF):1382.6064[M+H]+,1404.5900[M+Na]+,C70H88FN7O21.
实施例28:液相合成共缀物MDC-407
将90.7mg(1.0eq)多西紫杉醇2′-O-丁二酸单酯、11.5mg(1.0eq)HOSu和19.2mg(1.0eq)EDC·HCl溶于二甲基亚砜中,室温反应4小时;然后将49.2mg(1.0eq)胞壁酰二肽简化物MDA-207少量多次地加入二甲基亚砜中,用N-甲基吗啉将反应体系pH值调节至7~8,继续反应4小时。反应完全后,向反应体系内加入大量水,体系内析出白色固体,过滤,得到目标产物粗品,经ODS柱层析纯化,冷冻干燥,得到117.4mg固体,产率85%,m.p.=174~175℃。
1H-NMR(500MHz,DMSO-d6):4.43(1H,br.s,1-OH),5.41(1H,d,J=7.5Hz,2-H),3.65(1H,d,J=7.5Hz,3-H),4.91(1H,m,5-H),1.66(1H,m,6-Ha),2.25(1H,m,6-Hb),4.05(1H,m,7-H),5.09(1H,s,10-H),5.80(1H,m,13-H),1.64(1H,m,14-Ha),1.82(1H,m,14-Hb),0.99(3H,s,16-H),102(3H,s,17-H),1.68(3H,s,18-H),1.51(3H,s,19-H),4.02(1H,m,20-Ha),4.05(1H,d,J=9.0Hz,20-Hb), 2.22(3H,s,4-OCOCH3),5.09(1H,m,2′-H),5.09(1H,m,3′-H),7.86(1H,m,3′-NH),7.31(2H,m,ph-o-H),7.37(2H,d,J=7.5Hz,ph-m-H),7.17(1H,m,ph-p-H),7.99(2H,d,J=7.5Hz,OBz-o-H),7.65(2H,t,J=7.5Hz,OBz-m-H),7.74(1H,m,OBz-p-H),1.39(9H,s,-C(CH3)3),2.62(2H,m,22-H),2.36(2H,m,23-H),7.83(1H,m,25-H),3.00(2H,br.s,26-H),1.25(2H,m,27-H),1.26(2H,m,28-H),1.57(1H,m,29-Ha),1.64(1H,m,29-Hb),4.11(1H,m,30-H),6.97(1H,s,32-Ha),7.31(1H,s,32-Hb),7.92(1H,m,33-H),2.16(2H,m,35-H),1.74(1H,m,36-Ha),2.00(1H,m,36-Hb),4.14(1H,m,37-H),7.11(1H,s,39-Ha),7.31(1H,s,39-Hb),8.23(1H,d,J=8.5Hz,40-H),4.39(1H,m,42-H),1.28(3H,m,43-H),8.37(1H,d,J=6.5Hz,44-H),6.81(1H,d,J=16.5Hz,46-H),7.38(1H,d,J=16.5Hz,47-H),7.37(1H,m,49-H),7.22(1H,m,51-H),7.47(1H,m,52-H),7.41(1H,m,53-H).
13C-NMR(125MHz,DMSO-d6):77.3(1-C),75.3(2-C),46.4(3-C),80.8(4-C),84.2(5-C),36.9(6-C),71.2(7-C),57.4(8-C),209.8(9-C),74.2(10-C),136.5(11-C),137.3(12-C),71.6(13-C),35.2(14-C),43.3(15-C),26.9(16-C),21.2(17-C),14.1(18-C),10.3(19-C),75.9(20-C),165.1(2-OCO),170.0,22.9(4-OCOCH3),169.4(1′-C),75.5(2′-C),55.6(3′-C),155.7(3′-NHCO),78.9,28.6(-C(CH3)3),137.9(ph-q-C),127.9(ph-o-C),129.2(ph-m-C),128.5(ph-p-C),130.5(OBz-q-C),130.1(OBz-o-C),129.3(OBz-m-C),133.9(OBz-p-C),172.3(21-C),29.3(22-C),30.1(23-C),170.6(24-C),38.7(26-C),29.3(27-C),23.4(28-C),32.1(29-C),52.6(30-C),174.4(31-C),172.0(34-C),32.2(35-C),28.2(36-C),52.8(37-C),173.7(38-C),172.8(41-C),49.3(42-C),18.6(43-C),165.8(45-C),124.0(46-C),138.0(47-C),133.9(48-C),114.4(d,J=21.4Hz,49-C),162.9(d,J=242.4Hz,50-C),116.7(d,J=21.3Hz,51-C),131.4(d,J=8.5Hz,52-C),124.1(d,J=2.5Hz,53-C).
IR:3301.8(νOH andνNH),2969.9,2932.2(ν-CH),1656.3(νC=O),1529.6,1449.4(νC=C),1367.3,1245.0,1159.9,1069.2(δ-CH),981.7,783.2,707.7(δ=CH).
ESI-MS:1382.83[M+H]+,1404.64[M+Na]+.
HR-MS(TOF):1382.6118[M+H]+,1404.5942[M+Na]+,C70H88FN7O21.
实施例29:液相合成共缀物MDC-408
将90.7mg(1.0eq)多西紫杉醇2′-O-丁二酸单酯、11.5mg(1.0eq)HOSu和19.2mg(1.0eq)EDC·HCl溶于二甲基亚砜中,室温反应4小时;然后将51mg(1.0eq)胞壁酰二肽简化物MDA-208少量多次地加入二甲基亚砜中,用N-甲基吗啉将反应体系pH值调节至7~8,继续反应4小时。反应完全后,向反应体系内加入大量水,体系内析出白色固体,过滤,得到目标产物粗品,经ODS柱层析纯化,冷冻干燥,得到117.5mg固体,产率84%,m.p.=172~173℃。
1H-NMR(500MHz,DMSO-d6):4.43(1H,br.s,1-OH),5.41(1H,d,J=7.0Hz,2-H),3.64(1H,d, J=7.5Hz,3-H),4.90(1H,m,5-H),1.66(1H,m,6-Ha),2.25(1H,m,6-Hb),4.02(1H,m,7-H),5.09(1H,s,10-H),5.80(1H,m,13-H),1.64(1H,m,14-Ha),1.82(1H,m,14-Hb),0.99(3H,s,16-H),102(3H,s,17-H),1.70(3H,s,18-H),1.51(3H,s,19-H),4.02(1H,m,20-Ha),4.05(1H,m,20-Hb),2.25(3H,s,4-OCOCH3),5.09(1H,m,2′-H),5.09(1H,m,3′-H),7.87(1H,m,3′-NH),7.31(2H,m,ph-o-H),7.37(2H,d,J=7.5Hz,ph-m-H),7.19(1H,m,ph-p-H),7.99(2H,d,J=7.0Hz,OBz-o-H),7.66(2H,t,J=7.0Hz,OBz-m-H),7.73(1H,m,OBz-p-H),1.39(9H,s,-C(CH3)3),2.62(2H,m,22-H),2.39(2H,m,23-H),7.83(1H,m,25-H),3.01(2H,br.s,26-H),1.25(2H,m,27-H),1.26(2H,m,28-H),1.64(1H,m,29-Ha),1.67(1H,m,29-Hb),4.13(1H,m,30-H),6.97(1H,s,32-Ha),7.31(1H,s,32-Hb),7.92(1H,m,33-H),2.16(2H,m,35-H),1.78(1H,m,36-Ha),2.00(1H,m,36-Hb),4.14(1H,m,37-H),7.11(1H,s,39-Ha),7.31(1H,s,39-Hb),8.22(1H,d,J=8.0Hz,40-H),4.40(1H,m,42-H),1.28(3H,m,43-H),8.34(1H,d,J=7.0Hz,44-H),6.74(1H,d,J=15.5Hz,46-H),7.38(1H,d,J=15.5Hz,47-H),7.68(1H,m,50-H),7.45(1H,m,52-H),7.49(1H,m,53-H).
13C-NMR(125MHz,DMSO-d6):77.3(1-C),75.3(2-C),46.4(3-C),80.8(4-C),84.2(5-C),37.0(6-C),71.2(7-C),57.4(8-C),209.8(9-C),74.2(10-C),136.5(11-C),137.3(12-C),71.6(13-C),35.2(14-C),43.3(15-C),26.9(16-C),21.2(17-C),14.1(18-C),10.3(19-C),75.9(20-C),165.0(2-OCO),170.0,22.9(4-OCOCH3),169.4(1′-C),75.5(2′-C),55.6(3′-C),155.7(3′-NHCO),79.0,28.6(-C(CH3)3),138.0ph-q-C),127.9(ph-o-C),129.1(ph-m-C),128.5(ph-p-C),130.5(OBz-q-C),130.0(OBz-o-C),129.1(OBz-m-C),133.9(OBz-p-C),172.3(21-C),29.3(22-C),30.1(23-C),170.4(24-C),38.7(26-C),29.3(27-C),23.4(28-C),32.1(29-C),52.6(30-C),174.4(31-C),172.0(34-C),32.2(35-C),28.2(36-C),52.8(37-C),173.7(38-C),172.7(41-C),49.3(42-C),18.7(43-C),165.7(45-C),123.8(s,46-C),137.3(s,47-C),133.3(m,48-C),118.6(d,J=17.1Hz,49-C),151.2(m,50-C),149.3(dd,J=34.8and13.0Hz,51-C),116.7(d,J=17.6Hz,52-C),125.1(m,53-C).
IR:3308.5(νOH andνNH),2977.6,2936.9(ν-CH),1659.6(νC=O),1517.9,1452.4(νC=C),1368.3,1274.8,1247.4,1161.3(δ-CH),981.7,775.8,707.9(δ=CH).
ESI-MS:1400.82[M+H]+,1422.63[M+Na]+.
HR-MS(TOF):1400.6014[M+H]+,1422.5825[M+Na]+,C70H87F2N7O21.
生物学实施例
体外活性测试部分
实施例30:
本发明的化合物MDC-400送往美国国立癌症研究院(NCI)进行体外抗肿瘤活性筛选,针对60个人源肿瘤细胞株的实验结果表明,该类型共缀物的生长抑制50%值(GI50值)与紫杉醇保持在相同的数量级范围内,而半数致死浓度(LC50)都大于10μM。实验结果参见附图1。
本发明的化合物MDC-308、MDC-403、MDC-404、MDC-405、MDC-406、MDC-407和MDC-408针对10个人源肿瘤细胞株进行了体外实验筛选研究,同样,这些共缀物也保持在与者多西紫杉醇相同的50%抑制浓度(IC50)。实验结果参见附图2-3。